<DOC>
	<DOCNO>NCT01919008</DOCNO>
	<brief_summary>This study compare pharmacokinetics FK949E low dose tablet FK949E high dose tablet non-elderly patient major depressive disorder . The safety FK949E population also evaluate .</brief_summary>
	<brief_title>Comparison Plasma Concentration Changes Between Two Types Tablets FK949E Administration Patients With Major Depressive Disorder</brief_title>
	<detailed_description>The objective study compare pharmacokinetics FK949E low dose tablet FK949E high dose tablet non-elderly patient major depressive disorder 2 × 2 crossover design . The safety FK949E population also evaluate .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Patients consider able understand follow subject requirement , judge investigator/subinvestigator . Patients diagnose major depressive disorder accord DSMIVTR mean M.I.N.I . BMI : 17.6 ( inclusive ) 26.4 ( exclusive ) . Current past history DSMIVTR Axis I disorder , except major depressive disorder , within past 6 month inform consent . Concurrent DSMIVTR Axis II disorder consider greatly affect patient 's current mental status . Current past history dependence substance ( caffeine nicotine ) history abuse dependence alcohol . Unable suspend treatment inducer inhibitor drugmetabolizing enzyme , cytochrome P450 3A4 ( CYP3A4 ) , 14 day screen assessment throughout study . Patients could use appropriate contraception ( condom ) study . Patients pregnant lactate . Patients ( carrier ) document suspected renal failure , hepatic failure , serious cardiac disease , hepatitis B , hepatitis C , acquire immunodeficiency syndrome ( AIDS ) . Patients receive treatment hypertension , patient concurrent hypertension unstable angina may worsen study may affect study result base clinical judgment investigator/subinvestigator . Patients concurrent hypotension ( criterion hypotension : systolic blood pressure le 100 mmHg ) , orthostatic hypotension Patients mean QTcF interval ≥450 ms 12lead ECG screen assessment Patients risk torsades de pointe ( e.g. , history QT prolongation , familial long QT syndrome ) . Concurrent malabsorption syndrome , hepatic disease , condition may affect absorption and/or metabolism study drug . Concurrent malignancy history cure malignancy within 5 year Current past history cerebrovascular disease transient ischemic attack ( TIA ) . Received electroconvulsive therapy within 90 day screen assessment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>FK949E</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Major Depressive Disorder</keyword>
</DOC>